Prostate cancer affects millions of men worldwide, often leading to complex and long-term treatment plans. In recent years, mistletoe therapy has gained attention as a complementary approach to support conventional prostate cancer treatments. ABNOBA GmbH, a Germany-based pharmaceutical company with a strong research foundation, has been at the forefront of producing pharmaceutical-grade mistletoe extracts used in integrative oncology.
Mistletoe (Viscum album) is not just a holiday symbol—it has been used in European cancer care for over a century. Its biologically active compounds are believed to stimulate the immune system, reduce inflammation, and promote overall resilience in cancer patients. For men undergoing treatment for prostate cancer, mistletoe therapy may help alleviate fatigue, enhance energy levels, improve appetite, and provide emotional balance during and after treatment.
Several clinical studies and real-world experiences have shown that mistletoe therapy may contribute to better tolerance of chemotherapy or radiation and improve quality of life. Though not a cure, it is used widely in Germany and Switzerland as an adjunct to standard cancer therapies.
ABNOBA India is committed to bringing this integrative approach to Indian healthcare by making high-quality mistletoe preparations more accessible to patients and physicians. It is crucial, however, to consult with qualified oncologists or integrative medicine practitioners before beginning mistletoe therapy to ensure its safe and effective use.
With growing global interest in holistic cancer treatment, mistletoe is emerging as a natural ally in the journey of prostate cancer care.
